ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK–(Company WIRE)–#Motion–Bragar Eagel & Squire, P.C., a nationally identified shareholder rights legislation firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of lengthy-expression stockholders subsequent a class action grievance that was filed from Athira on June 25, 2021 with a Course Period of time from September 17, 2020 to June 17, 2021. Our investigation considerations whether the board of directors of Athira have breached their fiduciary responsibilities to the company.
On June 17, 2021, soon after the market place shut, Athira introduced that it had placed its president and Chief Govt Officer, Dr. Leen Kawas (“Kawas”), on leave pending a evaluation of actions stemming from doctoral exploration she done when at Washington State University (“WSU”).
The same working day, STAT printed an write-up stating that WSU was investigating statements that Dr. Kawas “published numerous papers containing altered pictures whilst she was a graduate student.” These papers “are foundational to Athira’s initiatives to handle Alzheimer’s” for the reason that they “established that a specific molecule has an effect on the activity of HGF.” While Athira is developing a distinct molecule than the a person Kawas examined in the papers at situation, her “doctoral perform laid the organic groundwork that Athira proceeds to use in their approach to managing Alzheimer’s.”
The Registration Statement was materially fake and deceptive and omitted to state: (1) that Kawas had printed exploration papers made up of improperly altered photographs while she was a graduate pupil (2) that this purported exploration was foundational to Athira’s attempts to produce treatment plans for Alzheimer’s mainly because it laid the biological groundwork that Athira was applying in its method to treating Alzheimer’s (3) that, as a final result, Athira’s intellectual property and merchandise progress for the therapy of Alzheimer’s were being based mostly on invalid research and (4) that, as a consequence of the foregoing, Defendants’ optimistic statements about the Company’s enterprise, operations, and prospective buyers, had been materially deceptive and/or lacked a acceptable basis.
If you are a very long-phrase stockholder of Athira, have information, would like to discover more about these claims, or have any concerns regarding this announcement or your legal rights or passions with respect to these issues, please speak to Brandon Walker or Alexandra B. Raymond by e-mail at [email protected], or phone at (212) 355-4648, or by filling out this get in touch with kind. There is no charge or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law agency with offices in New York and California. The organization represents individual and institutional investors in industrial, securities, by-product, and other sophisticated litigation in condition and federal courts across the country. For much more information and facts about the business, remember to take a look at www.bespc.com. Legal professional promoting. Prior effects do not assurance identical results.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
